BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.620
-0.040 (-2.41%)
At close: Feb 11, 2026, 4:00 PM EST
1.650
+0.030 (1.85%)
After-hours: Feb 11, 2026, 7:43 PM EST
BioXcel Therapeutics Employees
BioXcel Therapeutics had 37 employees as of December 31, 2024. The number of employees decreased by 37 or -50.00% compared to the previous year.
Employees
37
Change (1Y)
-37
Growth (1Y)
-50.00%
Revenue / Employee
$20,324
Profits / Employee
-$1,843,541
Market Cap
35.43M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 37 | -37 | -50.00% |
| Dec 31, 2023 | 74 | -109 | -59.56% |
| Dec 31, 2022 | 183 | 94 | 105.62% |
| Dec 31, 2021 | 89 | 39 | 78.00% |
| Dec 31, 2020 | 50 | 26 | 108.33% |
| Sep 30, 2020 | 40 | 17 | 73.91% |
| Jun 30, 2020 | 31 | 11 | 55.00% |
| Mar 31, 2020 | 27 | 8 | 42.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| InterCure | 320 |
| Zhengye Biotechnology Holding | 277 |
| Rockwell Medical | 244 |
| Cumberland Pharmaceuticals | 91 |
| Aytu BioPharma | 83 |
| Assertio Holdings | 58 |
| SCYNEXIS | 28 |
| Talphera | 13 |
BTAI News
- 22 days ago - BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting - GlobeNewsWire
- 27 days ago - Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 4 weeks ago - BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting - GlobeNewsWire
- 5 weeks ago - BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI® - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics, Inc. (BTAI) Discussion of Managing Acute Agitation in Schizophrenia and Bipolar Disorders at Home Transcript - Seeking Alpha
- 2 months ago - Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease - GlobeNewsWire
- 4 months ago - BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes - GlobeNewsWire